A mouse model was engineered to selectively disrupt GPR3-mediated β-arrestin signaling while retaining G protein signaling, enabling precise investigation of Alzheimer's disease pathology. This approach reduces soluble amyloid-β levels, decreases both the area and compaction of amyloid plaques, and enhances glial hypertrophy. By targeting specific signaling routes, the model allows researchers to study disease progression without the adverse effects typically seen with complete GPR3 deficiency, such as anxiety, reduced fertility, and memory impairment.